DDAVP in childhood nocturnal enuresis.
A double-blind study of 18 children aged 6--12 years suffering from primary nocturnal enuresis without signs of underlying organic disease is reported. 20 microgram of DDAVP (desamino-D-arginine vasopressin, Minirin) was given intranasally at bedtime. The effect was prompt and satisfactory in 8 children and relatively good in another 8 children. No adverse effects were noted. DDAVP is advocated for temporary use in children with nocturnal enuresis needing immediate help.
D001127:Arginine Vasopressin / Q000627:therapeutic use*; D002648:Child; D002940:Circadian Rhythm; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004775:Enuresis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D010919:Placebos; D011247:Pregnancy
D010919:Placebos; D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin